keyword
MENU ▼
Read by QxMD icon Read
search

Hepatic veno occlusive disease

keyword
https://www.readbyqxmd.com/read/30465738/pyrrolizidine-alkaloid-induced-alterations-of-prostanoid-synthesis-in-human-endothelial-cells
#1
Johanna Ebmeyer, Jessica Behrend, Mario Lorenz, Georgia Günther, Raymond Reif, Jan G Hengstler, Albert Braeuning, Alfonso Lampen, Stefanie Hessel-Pras
Pyrrolizidine alkaloids (PA) are a group of secondary plant metabolites belonging to the most widely distributed natural toxins. PA intoxication of humans leads to severe liver damage, such as hepatomegaly, hepatic necrosis, fibrosis and cirrhosis. An acute consequence observed after ingestion of high amounts of PA is veno-occlusive disease (VOD) where the hepatic sinusoidal endothelial cells are affected. However, the mechanisms leading to VOD after PA intoxication remain predominantly unknown. Thus, we investigated PA-induced molecular effects on human umbilical vein endothelial cells (HUVEC)...
November 19, 2018: Chemico-biological Interactions
https://www.readbyqxmd.com/read/30367628/risk-factors-for-hepatic-veno-occlusive-disease-caused-by-gynura-segetum-a-retrospective-study
#2
Yan Wang, Dan Qiao, Ya Li, Feng Xu
BACKGROUND: Hepatic veno-occlusive disease (HVOD) caused by Gynura segetum has been increasingly reported in China in recent years. The aim of this retrospective study was to identify independent prognostic markers for survival in patients with Gynura segetum-induced HVOD and to evaluate the effect of anticoagulants and transjugular intrahepatic portosystemic shunt (TIPS) on survival rate. METHODS: Clinical data including symptoms, signs, imaging characteristics, laboratory test results, results of liver tissue biopsies, type of treatment during follow-up and clinical outcomes were collected...
October 26, 2018: BMC Gastroenterology
https://www.readbyqxmd.com/read/30350914/treatment-of-hepatic-veno-occlusive-disease-in-children-with-n-acetylcysteine
#3
Anselm Chi-Wai Lee, LeLe Aung
In our institution, hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) has been treated with N-acetylcysteine (NAC) since 2008-a loading dose of 150 mg/kg, followed by 12 doses of 70 mg/kg 6 hourly. Nine children were diagnosed with hepatic VOD/SOS. Hepatic VOD/SOS occurred in seven children after stem cell transplantation and two were receiving chemotherapy for Wilms tumor. Their clinical severity was classified as moderate in two and severe in seven by the European Society for Blood and Marrow Transplantation criteria...
October 23, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/30348695/soluble-thrombomodulin-attenuates-endothelial-cell-damage-in-hepatic-sinusoidal-obstruction-syndrome
#4
Satoshi Takada, Tomoharu Miyashita, Yasuhiko Yamamoto, Shunsuke Kanou, Seiichi Munesue, Yoshinao Ohbatake, Shinichi Nakanuma, Koichi Okamoto, Seisho Sakai, Jun Kinoshita, Isamu Makino, Keishi Nakamura, Hidehiro Tajima, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Tetsuo Ohta
BACKGROUND: Hepatic sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease, is a form of drug-induced liver injury, the initial morphological changes associated with which occur in liver sinusoidal endothelial cells (LSECs). Recombinant human soluble thrombomodulin (rTM) is reported to have anti-inflammatory and cytoprotective effects. Therefore, we investigated the ability of rTM to protect endothelial cells and enhance their functions in a monocrotaline (MCT)-induced model of SOS...
November 2018: In Vivo
https://www.readbyqxmd.com/read/30310977/-liver-injury-induced-by-immune-checkpoint-inhibitor-therapy-example-of-an-immune-mediated-drug-side-effect
#5
REVIEW
B K Straub, D A Ridder, A Schad, C Loquai, J M Schattenberg
BACKGROUND: Drug-induced liver injury is increasing, especially in elderly patients with polymedication and multimorbidity. OBJECTIVES: Clinicopathologic correlation of immune-mediated liver injury, specifically liver injury following therapy with immune checkpoint inhibitors against PD-1, PDL-1, and CTLA4. METHODS: Histologic assessment of liver biopsies of nine patients after therapy with immune checkpoint inhibitors and correlation with clinical parameters...
November 2018: Der Pathologe
https://www.readbyqxmd.com/read/30302228/defibrotide-for-the-treatment-of-hepatic-veno-occlusive-disease-sinusoidal-obstruction-syndrome-with-multiorgan-failure
#6
REVIEW
Paul G Richardson, Stephan A Grupp, Antonio Pagliuca, Amrita Krishnan, Vincent T Ho, Selim Corbacioglu
Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening and unpredictable complication of hematopoietic stem cell transplantation (HSCT). Characterized by a prothrombotic-hypofibrinolytic state, VOD/SOS typically presents with hyperbilirubinemia, ascites, weight gain and painful hepatomegaly; VOD/SOS with multiorgan failure may be associated with >80% mortality. Treatment has been mainly supportive. However, defibrotide is now approved in the USA for treatment of hepatic VOD/SOS with renal or pulmonary dysfunction following HSCT and in the European Union for treatment of severe hepatic VOD/SOS post-HSCT...
November 2017: International Journal of Hematologic Oncology
https://www.readbyqxmd.com/read/30210742/transient-elastography-te-is-a-useful-tool-for-assessing-the-response-of-liver-iron-chelation-in-sickle-cell-disease-patients
#7
Sophia Delicou, Konstantinos Maragkos, Maria Tambaki, Dimitrios Kountouras, John Koskinas
Sickle cell disease patients often need regular blood transfusions to improve both the quality of life and survival from the veno-occlusive complications of the disease. Deferasirox, a convenient long acting oral agent, has recently been introduced in clinical practice with promising efficacy. This study aims to evaluate the association of liver stiffness and possible fibrosis with iron deposition and confirm the use of elastography as a validated test of responding to chelation with low cost and easy access...
2018: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/30196935/economic-burden-of-veno-occlusive-disease-in-patients-with-b-cell-acute-lymphoblastic-leukemia-in-the-united-states
#8
Xinke Zhang, Xue Song, Lorena Lopez-Gonzalez, Krutika Jariwala-Parikh, Vadim Romanov, Ze Cong
PURPOSE: The goal of this study was to evaluate the incidence, inpatient mortality, and economic burden of hepatic veno-occlusive disease (VOD) in adults with B-cell acute lymphoblastic leukemia (ALL) in the United States. METHODS: Using MarketScan Commercial Claims and Encounters Database and Medicare Supplemental and Coordination of Benefits Database, data for patients with B-cell ALL from April 1, 2009, to October 31, 2016, were extracted by using diagnosis codes...
September 6, 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/30181580/veno-occlusive-disease-after-high-dose-busulfan-melphalan-in-neuroblastoma
#9
Tal Schechter, Evelio Perez-Albuerne, Tiffany F Lin, Meredith S Irwin, Mohammed Essa, Ami V Desai, Haydar Frangoul, Gregory Yanik, L Lee Dupuis, David Jacobsohn, Morris Kletzel, Mark Ranalli, Sandeep Soni, Alix E Seif, Stephan Grupp, Christopher C Dvorak
Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma patients who underwent autologous SCT with busulfan and melphalan (BuMel) at eight centers following Children's Oncology Group (COG)-based induction chemotherapy. Data regarding the patients, SCT characteristics, busulfan steady-state concentrations, incidence of VOD, and survival were evaluated...
September 4, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/30081073/early-clinical-predictors-of-hepatic-veno-occlusive-disease-sinusoidal-obstruction-syndrome-after-myeloablative-stem-cell-transplantation
#10
Lindsey E Roeker, Haesook T Kim, Brett Glotzbecker, Prashant Nageshwar, Sarah Nikiforow, John Koreth, Philippe Armand, Corey Cutler, Edwin P Alyea, Joseph H Antin, Paul G Richardson, Robert J Soiffer, Vincent T Ho
Hepatic veno-occlusive disease (VOD), or sinusoidal obstruction syndrome (SOS), is a serious complication of hematopoietic stem cell transplantation (HSCT) with mortality in its severe form exceeding 80%. Although the incidence of VOD/SOS has fallen with contemporary transplantation practices, the increasing use of inotuzumab, the return of gemtuzumab, and the popularity of pharmacokinetic-guided high-dose busulfan may impact incidence. Early intervention with defibrotide improves survival, but prompt diagnosis can be difficult...
August 3, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/30060329/-clinical-outcome-of-allogeneic-hematopoietic-stem-cell-transplantation-with-flag-sequential-busulfan-cyclophosphamide-conditioning-regimen-for-refractory-relapsed-acute-myeloid-leukemia
#11
W Liu, Y Li, Z X Qiu, Y Yin, Y H Sun, W L Xu, Q Wang, Z Y Liang, Y J Dong, L H Wang, Q N Cen, M J Wang, W S Wang, J P Ou, H Y Ren
Objective: To investigate the therapeutic effects of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with FLAG sequential busulfan/cyclophosphamide(Bu/Cy) conditioning regimen for refractory/relapsed acute myeloid leukemia. Methods: From February 2012 to June 2017, 21 patients with refractory/relapsed acute myeloid leukemia underwent allo-HSCT with FLAG sequential Bu/Cy conditioning regimen. Transplantation-related complications and clinical outcome were retrospectively analyzed. Results: After conditioning, no hepatic veno-occlusive disease (VOD) and grade Ⅲ hemorrhagic cystitis occurred...
August 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29996265/-a-clinical-analysis-of-hepatic-veno-occlusive-disease-after-hematopoietic-stem-cell-transplantation
#12
C J Qin, L J Liu, Z M Zhang, L Luo, Y R Lai, Q C Li
Objective: To analyze the outcome and the prognostic factors of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). Methods: A total of 797 patients receiving HSCT were analyzed retrospectively. The prophylaxis regimen of HVOD in the First Affiliated Hospital of Guangxi Medical University consisted of low molecular weight heparin and lipoprostaglandin E1 (PGE1). Results: Fifty-nine patients (7.4%) developed HVOD at 3-49 days after HSCT (median 12 days). Age younger than 15 years at transplant( HR = 6...
July 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29970140/fulminant-hepatitis-due-to-very-severe-sinusoidal-obstruction-syndrome-sos-vod-after-autologous-peripheral-stem-cell-transplantation-a-case-report
#13
Emmanuelle Tavernier, Emilie Chalayer, Jérôme Cornillon, Anne Pouvaret, Jean-Alain Martignoles, François Casteillo, Jérémy Terreaux, Elisabeth Daguenet, Denis Guyotat
BACKGROUND: Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (SOS/VOD), is a potentially fatal complication of allogeneic or autologous hematopoietic stem cell transplantation. A plethora of transplant and patient-related risk factors predispose to SOS/VOD and should be taken into account for prognosis assessment as well as for adequate therapeutic intervention. CASE PRESENTATION: We describe the case of a mantle cell lymphoma patient who developed a fulminant hepatitis following oxaliplatin-containing intensive chemotherapy and autologous transplantation...
July 3, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29945939/the-use-of-defibrotide-in-blood-and-marrow-transplantation
#14
REVIEW
Paul G Richardson, Enric Carreras, Massimo Iacobelli, Bijan Nejadnik
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of conditioning during hematopoietic stem cell transplantation (HSCT) or chemotherapy without HSCT, with a historically reported mean incidence of 13.7% post-HSCT. Typical symptoms of VOD/SOS may include hyperbilirubinemia, painful hepatomegaly, weight gain, and ascites. Defibrotide, a polydisperse mixture of predominantly single-stranded polydeoxyribonucleotides, is currently the only therapy approved to treat hepatic VOD/SOS with pulmonary/renal dysfunction (ie, multiorgan dysfunction/multiorgan failure [MOD/MOF]) following HSCT in the United States and to treat severe hepatic VOD/SOS post-HSCT in the European Union...
June 26, 2018: Blood Advances
https://www.readbyqxmd.com/read/29928989/risk-score-for-the-development-of-veno-occlusive-disease-after-allogeneic-hematopoietic-cell-transplant
#15
Christopher Strouse, Ying Zhang, Mei-Jie Zhang, Alyssa DiGilio, Marcelo Pasquini, Mary M Horowitz, Stephanie Lee, Vincent Ho, Muthalagu Ramanathan, Wichai Chinratanalab, Alison Loren, Linda J Burns, Andrew Artz, Kathleen F Villa, Wael Saber
A risk score identifying patients at high risk for veno-occlusive disease (VOD) may aid efforts to study preventive strategies for this uncommon complication of hematopoietic cell transplantation (HCT). Patients receiving a first allogeneic HCT between 2008 and 2013 as reported to the Center for International Blood and Marrow Transplant Research (N = 13,097) were randomly divided into training and validation sets. Independent prognostic factors for development of VOD by day +100 after HCT were identified with a multivariate logistic regression model...
October 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29895929/hepatic-veno-occlusive-disease-following-sirolimus-based-immune-suppression
#16
Farhad Khimani, George B McDonald, Howard M Shulman, Brian Betts, Frederick Locke, Hugo Fernandez, Claudio Anasetti, Joseph Pidala
Sirolimus-based graft vs. host disease (GVHD) prophylaxis is associated with higher incidence of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after allogeneic hematopoietic cell transplantation (HCT). However, whether the clinical manifestations and prognosis of VOD/SOS differs when diagnosed in the setting of sirolimus-based GVHD prophylaxis is not well studied. To address this question, we examined presenting features and treatment outcome of VOD/SOS cases identified in a large retrospective cohort of consecutive HCT procedures (n = 818 total, sirolimus (SIR)/tacrolimus (TAC) n = 308, and methotrexate (MTX) or mycophenolate mofetil (MMF)/TAC n = 510)...
June 12, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29873895/defibrotide-for-the-treatment-of-hepatic-veno-occlusive-disease-sinusoidal-obstruction-syndrome-following-nontransplant-associated-chemotherapy-final-results-from-a-post-hoc-analysis-of-data-from-an-expanded-access-program
#17
Nancy A Kernan, Paul G Richardson, Angela R Smith, Brandon M Triplett, Joseph H Antin, Leslie Lehmann, Yoav Messinger, Wei Liang, Robin Hume, William Tappe, Robert J Soiffer, Stephan A Grupp
BACKGROUND: Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially fatal complication of conditioning for hematopoietic stem cell transplantation (HSCT) but can occur after nontransplant-associated chemotherapy. Following HSCT, VOD/SOS with multi-organ dysfunction (MOD) may be associated with >80% mortality. Defibrotide is approved to treat severe hepatic VOD/SOS post-HSCT in patients aged >1 month in the European Union and hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the United States...
October 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29803752/novel-ultrasonographic-scoring-system-of-sinusoidal-obstruction-syndrome-after-hematopoietic-stem-cell-transplantation
#18
Mutsumi Nishida, Kaoru Kahata, Eiko Hayase, Akio Shigematsu, Megumi Sato, Yusuke Kudo, Satomi Omotehara, Takahito Iwai, Junichi Sugita, Hitoshi Shibuya, Chikara Shimizu, Takanori Teshima
Sinusoidal obstruction syndrome (SOS)/hepatic veno-occlusive disease (VOD) is a well-documented complication after hematopoietic stem cell transplantation (HSCT). Transabdominal ultrasonography (US) enables the visualization of blood flow abnormalities and is therefore useful for the diagnosis of SOS/VOD. We herein prospectively evaluated accuracy of a novel US diagnostic scoring system of SOS/VOD based on US findings. We carried out US in 106 patients on day 14 and when SOS/VOD was suspected after allogeneic HSCT...
September 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29767845/final-results-from-a-defibrotide-treatment-ind-study-for-patients-with-hepatic-veno-occlusive-disease-sinusoidal-obstruction-syndrome
#19
Nancy A Kernan, Stephan Grupp, Angela R Smith, Sally Arai, Brandon Triplett, Joseph H Antin, Leslie Lehmann, Tsiporah Shore, Vincent T Ho, Nancy Bunin, Massimo Iacobelli, Wei Liang, Robin Hume, William Tappe, Robert Soiffer, Paul Richardson
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of haematopoietic stem cell transplant (HSCT) conditioning and chemotherapy. Defibrotide is approved for treatment of hepatic VOD/SOS with pulmonary or renal dysfunction [i.e., multi-organ dysfunction (MOD)] after HSCT in the United States and severe VOD/SOS after HSCT in patients aged older than 1 month in the European Union. Defibrotide was available as an investigational drug by an expanded-access treatment programme (T-IND; NCT00628498)...
June 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29750747/haploidentical-donor-transplantation-using-a-novel-clofarabine-containing-conditioning-regimen-for-very-high-risk-hematologic-malignant-neoplasms
#20
Akshay Sharma, Guolian Kang, Anusha Sunkara, Hiroto Inaba, Sima Jeha, Shane J Cross, Terrence Geiger, Brandon Triplett
Recurrent/refractory hematologic malignancies have a poor prognosis, and there is a need for novel treatment regimens that can be tolerated by this heavily pretreated patient group. Clofarabine has antileukemic activity with an acceptable toxicity profile. In a phase I clinical trial (NCT00824135), we substituted clofarabine for fludarabine in a well-established reduced-intensity conditioning regimen for a T cell-depleted, mismatched-related (haploidentical) donor transplant backbone and explored the maximum tolerated dose of clofarabine in this combination in 15 patients undergoing hematopoietic cell transplantation for recurrent/refractory or secondary leukemia...
November 2018: Journal of Pediatric Hematology/oncology
keyword
keyword
162266
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"